TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2024
Gross margin
34.8%−7.3 pts over 5 years
Operating margin
-34.4%−7.7 pts over 5 years
Net margin
-51.6%−19.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.3% | -8.8% | -7.4% | – | |
| Gross profit | +10.2% | -13.8% | -10.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on assets | – | -20.5% | -39.1% | |
| Current ratio | – | 3.67 | 1.28 | |
| Net debt to EBITDA | -0.77× | -2.77× | 0.24× | |
| Interest coverage | 3.3× | -3.7× | -2.2× | |
| Inventory turnover | – | 1.7× | 2.0× | |
| Capex to revenue | 7.1% | 2.3% | 0.7% | |
| Diluted shares | 110M | 102M | 359M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Trinity Biotech generated $53.66M from operations and spent $7.30M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$53.66M
Used
$7.30M
Capital expenditure$7.30M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
4of 9 tests passed in fiscal 2024. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$31.79M
- Cash generatingOperating cash flow above zero-$4.19M
- Return on assets improvedROA up on the prior year-26.1% → -53.5%
- Earnings backed by cashOperating cash flow above net income-$4.19M vs -$31.79M
- Less leverageLong-term debt to assets fell0.4% → 0.2%
- Better liquidityCurrent ratio rose2.60 → 1.28
- No dilutionShare count did not rise153M → 359M
- Gross margin improvedGross margin up on the prior year34.22% → 34.83%
- More efficientAsset turnover rose0.62 → 1.04